{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T04:32:53Z","timestamp":1792989173209,"version":"4.5.0"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.critrevonc.2025.104923","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T15:55:14Z","timestamp":1756828514000},"page":"104923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Is it a new era for intrahepatic cholangiocarcinoma?"],"prefix":"10.1016","volume":"215","author":[{"given":"Carolina","family":"Liguori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Benedetti","family":"Cacciaguerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Giampieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mocchegiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Sciortino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vivarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Niger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4629-7762","authenticated-orcid":false,"given":"Alessandro","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.critrevonc.2025.104923_bib1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104923_bib2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104923_bib3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","article-title":"EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma","volume":"79","author":"Alvaro","year":"2023","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104923_bib4","first-page":"93","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104923_bib5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"25","key":"10.1016\/j.critrevonc.2025.104923_bib6","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRAS G12C mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104923_bib7","doi-asserted-by":"crossref","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104923_bib8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","article-title":"Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma","volume":"71","author":"Bertuccio","year":"2019","journal-title":"J. Hepatol."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104923_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15174217","article-title":"Locoregional treatment in intrahepatic cholangiocarcinoma: which treatment for which patient?","volume":"15","author":"Bourien","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104923_bib10","first-page":"21","article-title":"Cholangiocarcinoma: epidemiology and risk factors","volume":"1","author":"Bragazzi","year":"2012","journal-title":"Transl. Gastrointest. Cancer"},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104923_bib11","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1200\/JCO.21.02568","article-title":"Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study","volume":"40","author":"Bridgewater","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104923_bib12","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Burris","year":"2024","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104923_bib13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaoncol.2019.3718","article-title":"Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial","volume":"6","author":"Cercek","year":"2020","journal-title":"JAMA Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104923_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103647","article-title":"Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment, and follow-up of patients with biliary tract cancer","volume":"9","author":"Chen","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2025.104923_bib15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/gutjnl-2017-315485","article-title":"Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma","volume":"68","author":"Chew","year":"2019","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104923_bib16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/liv.14089","article-title":"Surgery for cholangiocarcinoma","volume":"39","author":"Cillo","year":"2019","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104923_bib17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1245\/ASO.2003.03.091","article-title":"The role of staging laparoscopy in hepatobiliary malignancy: prospective analysis of 401 cases","volume":"10","author":"D\u2019Angelica","year":"2003","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104923_bib18","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1038\/s41416-023-02460-2","article-title":"Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy","volume":"129","author":"d'Abrigeon","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104923_bib19","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/jso.25323","article-title":"Staging laparoscopy among three subtypes of extra-hepatic biliary malignancy: a 15-year experience from 10 institutions","volume":"119","author":"Davidson","year":"2019","journal-title":"J. Surg. Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104923_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14246126","article-title":"The prognostic role of true radical resection in perihilar cholangiocarcinoma after improved evaluation of radial margin status","volume":"14","author":"De Bellis","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104923_bib21","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-14-1298","article-title":"Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence","volume":"20","author":"de Biasi","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104923_bib22","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/lt.25737","article-title":"Analysis of liver resection versus liver transplantation on outcome of small intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in the setting of cirrhosis","volume":"26","author":"De Martin","year":"2020","journal-title":"Liver Transpl."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104923_bib23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104923_bib24","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK Fusion-Positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104923_bib25","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata","year":"2018","journal-title":"Br. J. Surg."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104923_bib26","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study","volume":"37","author":"Edeline","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104923_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102258","article-title":"Locoregional therapies in patients with intrahepatic cholangiocarcinoma: a systematic review and pooled analysis","volume":"99","author":"Edeline","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104923_bib28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","article-title":"Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial","volume":"6","author":"Edeline","year":"2020","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104923_bib29","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.jhep.2023.09.006","article-title":"Corrigendum to \u201cEASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma\u201d","volume":"79","author":"European Association for the Study of the Liver","year":"2023","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104923_bib30","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1158\/2767-9764.CRC-24-0137","article-title":"A phase I study of KIN-3248, an irreversible Small-molecule Pan-FGFR inhibitor, in patients with advanced FGFR2\/3-driven solid tumors","volume":"4","author":"Garmezy","year":"2024","journal-title":"Cancer Res Commun."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104923_bib31","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/modpathol.2013.206","article-title":"BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma","volume":"27","author":"Goeppert","year":"2014","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104923_bib32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41416-018-0199-2","article-title":"Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma","volume":"120","author":"Goeppert","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104923_bib33","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-Rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104923_bib34","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211036544","article-title":"IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer","volume":"13","author":"Hack","year":"2021","journal-title":"Ther. Adv. Med Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104923_bib35","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104923_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2023.106994","article-title":"Impact of perioperative chemotherapy on survival in patients with cholangiocarcinoma undergoing curative resection","volume":"49","author":"Hassan","year":"2023","journal-title":"Eur. J. Surg. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104923_bib37","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/PAS.0000000000000670","article-title":"Distinct clinicopathologic and genetic features of 2 histologic subtypes of intrahepatic cholangiocarcinoma","volume":"40","author":"Hayashi","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104923_bib38","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/SLA.0000000000006365","article-title":"Recommendations on robotic hepato-pancreato-biliary surgery. The Paris Jury-Based consensus conference","volume":"281","author":"Hobeika","year":"2025","journal-title":"Ann. Surg."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.104923_bib39","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS G12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104923_bib40","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/jso.26370","article-title":"A comparison of surgical resection and liver transplantation in the treatment of intrahepatic cholangiocarcinoma in the era of modern chemotherapy: an analysis of The National cancer database","volume":"123","author":"Hue","year":"2021","journal-title":"J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104923_bib41","first-page":"102","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401-MITSUBA). j hepatobiliary pancreat sci","volume":"30","author":"Ioka","year":"2023"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104923_bib42","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/lt.26285","article-title":"A 3-decade, single-center experience of liver transplantation for cholangiocarcinoma: impact of era, tumor size, location, and neoadjuvant therapy","volume":"28","author":"Ito","year":"2022","journal-title":"Liver Transpl."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104923_bib43","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","article-title":"Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA registry","volume":"76","author":"Izquierdo-Sanchez","year":"2022","journal-title":"J. Hepatol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104923_bib44","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104923_bib45","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104923_bib46","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/MEG.0000000000001036","article-title":"Effects of liver cirrhosis and patient condition on clinical outcomes in intrahepatic cholangiocarcinoma: a retrospective analysis of 156 cases in a single center","volume":"30","author":"Jesper","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104923_bib47","doi-asserted-by":"crossref","first-page":"6","DOI":"10.14701\/ahbps.2020.24.1.6","article-title":"The role of down staging treatment in the management of locally advanced intrahepatic cholangiocarcinoma: review of literature and pooled analysis","volume":"24","author":"Kamarajah","year":"2020","journal-title":"Ann. Hepatobiliary Pancreat. Surg."},{"key":"10.1016\/j.critrevonc.2025.104923_bib48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.21037\/tgh-23-90","article-title":"Resection and reconstruction of the largest abdominal vein system (the inferior vena cava, hepatic, and portal vein): a narrative review","volume":"9","author":"Kaneko","year":"2024","journal-title":"Transl. Gastroenterol. Hepatol."},{"issue":"Suppl 3","key":"10.1016\/j.critrevonc.2025.104923_bib49","doi-asserted-by":"crossref","first-page":"S1093","DOI":"10.1245\/s10434-015-4768-9","article-title":"Downsizing Chemotherapy for Initially Unresectable Locally Advanced Biliary Tract Cancer Patients Treated with Gemcitabine Plus Cisplatin Combination Therapy Followed by Radical Surgery","volume":"22","author":"Kato","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"10391","key":"10.1016\/j.critrevonc.2025.104923_bib50","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104923_bib51","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104923_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2024.108010","article-title":"Short-term postoperative outcomes of lymphadenectomy for cholangiocarcinoma, hepatocellular carcinoma and colorectal liver metastases in the modern era of liver surgery: insights from the StuDoQ|Liver registry","volume":"50","author":"Knitter","year":"2024","journal-title":"Eur. J. Surg. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104923_bib53","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.3390\/jcm9092854","article-title":"Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers","volume":"9","author":"Lamarca","year":"2020","journal-title":"J. Clin. Med"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104923_bib54","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104923_bib55","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djz071","article-title":"Advanced intrahepatic cholangiocarcinoma: post hoc analysis of the ABC-01, -02, and -03 clinical trials","author":"Lamarca","year":"2019","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104923_bib56","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/bjs.10641","article-title":"Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma","volume":"105","author":"Le Roy","year":"2018","journal-title":"J. Brit Surg."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104923_bib57","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","article-title":"Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean cancer study group (KCSG-HB19-14)","volume":"8","author":"Lee","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104923_bib58","doi-asserted-by":"crossref","first-page":"52","DOI":"10.21037\/cco.2018.07.03","article-title":"Intrahepatic cholangiocarcinoma: the AJCC\/UICC 8th edition updates","volume":"7","author":"Lee","year":"2018","journal-title":"Chin. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104923_bib59","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/lt.25052","article-title":"Liver transplantation for intrahepatic cholangiocarcinoma","volume":"24","author":"Lee","year":"2018","journal-title":"Liver Transpl."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104923_bib60","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.ejso.2017.02.012","article-title":"The role of minimally invasive surgery in the treatment of cholangiocarcinoma","volume":"43","author":"Levi Sandri","year":"2017","journal-title":"Eur. J. Surg. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104923_bib61","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/modpathol.2013.241","article-title":"Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features","volume":"27","author":"Liau","year":"2014","journal-title":"Mod. Pathol."},{"issue":"32","key":"10.1016\/j.critrevonc.2025.104923_bib62","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.3748\/wjg.v29.i32.4815","article-title":"International experts consensus guidelines on robotic liver resection in 2023","volume":"29","author":"Liu","year":"2023","journal-title":"World J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104923_bib63","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.3390\/ijms23052707","article-title":"PD-1\/PD-L1 Immuno-Mediated therapy in NAFLD: advantages and obstacles in the treatment of advanced disease","volume":"23","author":"Lombardi","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104923_bib64","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1158\/2159-8290.CD-23-0153","article-title":"The MDM2-p53 antagonist brigimadlin (BI 907828) in patients with advanced or metastatic solid tumors: results of a phase ia, First-in-Human, Dose-Escalation study","volume":"13","author":"LoRusso","year":"2023","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104923_bib65","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2468-1253(18)30045-1","article-title":"Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series","volume":"3","author":"Lunsford","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104923_bib66","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1245\/s10434-023-13809-5","article-title":"NEO-GAP: a single-arm, phase II feasibility trial of neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for resectable, high-risk intrahepatic cholangiocarcinoma","volume":"30","author":"Maithel","year":"2023","journal-title":"Ann. Surg. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104923_bib67","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial","volume":"15","author":"Malka","year":"2014","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104923_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite Instability\/Mismatch Repair-Deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104923_bib69","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jhep.2019.11.020","article-title":"Liver resection and transplantation for intrahepatic cholangiocarcinoma","volume":"72","author":"Mazzaferro","year":"2020","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104923_bib70","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/ajt.16906","article-title":"Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma","volume":"22","author":"McMillan","year":"2022","journal-title":"Am. J. Transpl."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104923_bib71","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ueg2.12656","article-title":"Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: a multicenter real world cohort","volume":"12","author":"Mitzlaff","year":"2024","journal-title":"U. Eur. Gastroenterol. J."},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104923_bib72","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1200\/JCO.2023.41.16_suppl.4088","article-title":"Characterizing KRAS allele variants within biliary tract cancers","volume":"41","author":"Moffat","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104923_bib73","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","article-title":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial","volume":"30","author":"Morizane","year":"2019","journal-title":"Ann. Oncol."},{"issue":"36","key":"10.1016\/j.critrevonc.2025.104923_bib74","doi-asserted-by":"crossref","first-page":"58007","DOI":"10.18632\/oncotarget.11157","article-title":"Therapeutic implication of HER2 in advanced biliary tract cancer","volume":"7","author":"Nam","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104923_bib75","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/s12885-024-12225-6","article-title":"A phase II\/III randomized clinical trial of cisplatin plus gemcitabine and nabpaclitaxel (GAP) as preoperative chemotherapy versus immediate resection in patients with resectable biliary tract cancers (BTC) at high risk for recurrence: PURITY study","volume":"24","author":"Niger","year":"2024","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104923_bib76","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomized phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104923_bib77","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104923_bib78","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1200\/JCO.2022.40.16_suppl.4006","article-title":"Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): an investigator-initiated multicenter phase 2 study (HERB trial)","volume":"40","author":"Ohba","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104923_bib79","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.2217\/fon-2022-0214","article-title":"Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial","volume":"18","author":"Ohba","year":"2022","journal-title":"Future Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104923_bib80","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11523-024-01044-1","article-title":"Durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer: an exploratory analysis of Real-World data","volume":"19","author":"Olkus","year":"2024","journal-title":"Target Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104923_bib81","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104923_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113587","article-title":"Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: a joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies","volume":"200","author":"Parisi","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104923_bib83","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1186\/s12885-024-12584-0","article-title":"Erdafitinib in asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial","volume":"24","author":"Park","year":"2024","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104923_bib84","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.hpb.2022.12.006","article-title":"Laparoscopic versus open liver resections for intrahepatic cholangiocarcinoma and gallbladder cancer: the mayo clinic experience","volume":"25","author":"Pery","year":"2023","journal-title":"HPB (Oxf. )"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104923_bib85","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.21.00679","article-title":"Modified FOLFIRINOX versus CISGEM chemotherapy for patients with advanced biliary tract cancer (PRODIGE 38 AMEBICA): a randomized phase II study","volume":"40","author":"Phelip","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104923_bib86","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1200\/JCO.2023.41.16_suppl.3019","article-title":"Preliminary safety and efficacy of tinengotinib tablets as monotherapy and combination therapy in advanced solid tumors: a phase Ib\/II clinical trial","volume":"41","author":"Piha-Paul","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104923_bib87","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1007\/s00464-015-4430-4","article-title":"Safety and feasibility of laparoscopic liver resection with associated lymphadenectomy for intrahepatic cholangiocarcinoma: a propensity score-based case-matched analysis from a single institution","volume":"30","author":"Ratti","year":"2016","journal-title":"Surg. Endosc."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104923_bib88","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1245\/s10434-023-14807-3","article-title":"Minimally invasive approach provides oncological benefit in patients with high risk of very early recurrence (VER) after surgery for intrahepatic cholangiocarcinoma (iCCA)","volume":"31","author":"Ratti","year":"2024","journal-title":"Ann. Surg. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104923_bib89","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1111\/liv.15641","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: an early exploratory analysis of real-world data","volume":"43","author":"Rimini","year":"2023","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104923_bib90","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.sla.0000108702.45715.81","article-title":"Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma","volume":"239","author":"Robles","year":"2004","journal-title":"Ann. Surg."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104923_bib91","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","article-title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration","volume":"35","author":"Rodon","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104923_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1321683","article-title":"Clinical management of intrahepatic cholangiocarcinoma: surgical approaches and systemic therapies","volume":"14","author":"Ruff","year":"2024","journal-title":"Front Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104923_bib93","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1097\/SLA.0000000000000494","article-title":"Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a spanish matched cohort multicenter study","volume":"259","author":"Sapisochin","year":"2014","journal-title":"Ann. Surg."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104923_bib94","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/hep.28744","article-title":"Liver transplantation for \u201cvery early\u201d intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment","volume":"64","author":"Sapisochin","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104923_bib95","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/hep.32258","article-title":"Liver transplantation for intrahepatic cholangiocarcinoma: ready for prime time?","volume":"75","author":"Sapisochin","year":"2022","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104923_bib96","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/ajt.12591","article-title":"\u201cVery early\u201d intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients?","volume":"14","author":"Sapisochin","year":"2014","journal-title":"Am. J. Transpl."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104923_bib97","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","article-title":"Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study","volume":"8","author":"Shi","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"4_","key":"10.1016\/j.critrevonc.2025.104923_bib98","article-title":"SWOG 1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers","volume":"41","author":"Shroff","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104923_bib99","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104923_bib100","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1245\/s10434-019-07260-8","article-title":"Impact of anatomical versus Non-anatomical liver resection on Short- and Long-Term outcomes for patients with intrahepatic cholangiocarcinoma","volume":"26","author":"Si","year":"2019","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104923_bib101","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12885-017-3967-0","article-title":"Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study","volume":"18","author":"Siebenh\u00fcner","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2025.104923_bib102","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/JHC.S187121","article-title":"The immune modulation effect of locoregional therapies and its potential synergy with immunotherapy in hepatocellular carcinoma","volume":"7","author":"Singh","year":"2020","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104923_bib103","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejso.2021.08.009","article-title":"The role of lymphadenectomy in the surgical treatment of intrahepatic cholangiocarcinoma: a review","volume":"48","author":"Sposito","year":"2022","journal-title":"Eur. J. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104923_bib104","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jhep.2022.10.021","article-title":"Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node-negative intrahepatic cholangiocarcinoma","volume":"78","author":"Sposito","year":"2023","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104923_bib105","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion\u2013positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat. Med"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104923_bib106","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat. Med"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104923_bib107","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/2159-8290.CD-23-0475","article-title":"RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations","volume":"13","author":"Subbiah","year":"2023","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104923_bib108","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104923_bib109","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1200\/JCO.2022.40.16_suppl.4102","article-title":"Genomic profile of intrahepatic cholangiocarcinoma with MTAP loss","volume":"40","author":"Tang","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104923_bib110","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1245\/s10434-020-09478-3","article-title":"Neoadjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma: A Propensity Score Survival Analysis Supporting Use in Patients with High-Risk Disease","volume":"28","author":"Utuama","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104923_bib111","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104923_bib112","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104923_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1497415","article-title":"Durvalumab and pembrolizumab in advanced biliary tract cancer: a reconstructed patient-level mimic head-to-head comparative analysis","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2025.104923_bib114","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jss.2019.04.023","article-title":"Downstaging locally advanced cholangiocarcinoma pre-liver transplantation: a prospective pilot study","volume":"242","author":"Wong","year":"2019","journal-title":"J. Surg. Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104923_bib115","first-page":"217","article-title":"Interventional radiology locoregional therapies for intrahepatic cholangiocarcinoma","volume":"14","author":"Woodhead","year":"2024","journal-title":"Life (Basel)"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104923_bib116","doi-asserted-by":"crossref","first-page":"376","DOI":"10.5582\/bst.2020.03293","article-title":"Safety and feasibility of laparoscopic versus open liver resection with associated lymphadenectomy for intrahepatic cholangiocarcinoma","volume":"14","author":"Wu","year":"2020","journal-title":"Biosci. Trends"},{"key":"10.1016\/j.critrevonc.2025.104923_bib117","article-title":"Long-term outcomes of anatomic vs. Non-anatomic resection in intrahepatic cholangiocarcinoma with hepatolithiasis: a multicenter retrospective study","volume":"10","author":"Wu","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104923_bib118","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ejso.2019.03.023","article-title":"Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis","volume":"45","author":"Yadav","year":"2019","journal-title":"Eur J Surg Oncol"},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104923_bib119","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.2022.40.16_suppl.3095","article-title":"A phase Ia\/Ib, dose-escalation\/expansion study of BI 907828 in combination with BI 754091 (ezabenlimab) and BI 754111 in patients (pts) with advanced solid tumors","volume":"40","author":"Yamamoto","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104923_bib120","article-title":"Adjuvant tislelizumab combined with capecitabine for patients with biliary tract cancer with high risk of postoperative relapse (ACTIVE): primary analysis from a prospective cohort study","volume":"42","author":"Yang","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104923_bib121","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91823-x","article-title":"Primary tumor resection improves survival in patients with multifocal intrahepatic cholangiocarcinoma based on a population study","volume":"11","author":"Yin","year":"2021","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104923_bib122","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s11605-017-3499-6","article-title":"Perioperative and long-term outcome for intrahepatic cholangiocarcinoma: impact of major versus minor hepatectomy","volume":"21","author":"Zhang","year":"2017","journal-title":"J. Gastrointest. Surg."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104923_bib123","doi-asserted-by":"crossref","first-page":"e1187","DOI":"10.1097\/SLA.0000000000003788","article-title":"Number and station of lymph node metastasis after curative-intent resection of intrahepatic cholangiocarcinoma impact prognosis","volume":"274","author":"Zhang","year":"2021","journal-title":"Ann. Surg."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104923_bib124","doi-asserted-by":"crossref","first-page":"8184","DOI":"10.1002\/cam4.5620","article-title":"Adequate lymph node dissection is essential for accurate nodal staging in intrahepatic cholangiocarcinoma: a population-based study","volume":"12","author":"Zhu","year":"2023","journal-title":"Cancer Med"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:36:44Z","timestamp":1792985804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825003117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":124,"alternative-id":["S1040842825003117"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104923","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is it a new era for intrahepatic cholangiocarcinoma?","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104923","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104923"}}